The University of Colorado Boulder received a $569,210 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to conduct research on mechanisms of lipid A modification impacting antimicrobial resistance. The research aims to structurally and functionally characterize three proteins responsible for resistance to cationic antimicrobial peptides and the polymyxin antibiotic colistin, screen for inhibitory compounds, and develop quantitative in vitro and cell-based assays. This research provides insights into lipid A modification pathways that confer resistance to these critical antibiotics used to treat infections from multidrug-resistant gram-negative pathogens. The project will generate new targets, assays, and inhibitory probes to support future development of adjuvant drugs that can potentiate the efficacy of colistin against deadly resistant infections.
Generated 3/4/25, 2:13 AM